试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-04
LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
编号:NCT03711929登记状态:提前终止企业 / 申办者:Santen Inc.
药物 / 成分:DE-109 Intravitreal Injections、Sham Procedure、DE-109 Intravitreal Injections、DE-109 Intravitreal Injections (Open Label)
登记的停止原因(原文):Business decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-04
Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease
编号:NCT03870334登记状态:提前终止企业 / 申办者:NImmune Biopharma
药物 / 成分:BT-11 880 mg、Placebo
登记的停止原因(原文):Decision of Landos Biopharma (not related to safety or efficacy)
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-04
Pitolisant Effects on Alcohol Self-Administration in Heavy Drinkers
编号:NCT04596267登记状态:提前终止企业 / 申办者:Boston Medical Center
药物 / 成分:Pitolisant、Placebo
登记的停止原因(原文):Study funding was exhausted prior to reaching the recruitment goal due to pandemic related delays
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-04
A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer
编号:NCT04690855登记状态:提前终止企业 / 申办者:Mylin A. Torres, MD
药物 / 成分:Talazoparib、Atezolizumab、Radiation
登记的停止原因(原文):This study has been terminated due to Lack of Accrual.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-01
The Efficacy of Crotaline Fab Antivenom for Copperhead Snake Envenomations
编号:NCT00303303登记状态:提前终止企业 / 申办者:Wake Forest University Health Sciences
药物 / 成分:Crotaline Polyvalent Immune Fab (ovine) (active initial and maintenance therapy)、Crotaline Immune Fab (ovine) (active initial therapy; placebo maintenance therapy)、Placebo
登记的停止原因(原文):Study terminated due to declining enrollment; data analysis proceeding.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-01
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease
编号:NCT01559129登记状态:提前终止企业 / 申办者:Celgene
药物 / 成分:Pomalidomide (CC-4047)、Placebo
登记的停止原因(原文):Enrollment was stopped early (see limitations and caveats section).
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-01
Effect of Vitamin D Supplementation on Balance in CKD
编号:NCT03710161登记状态:提前终止企业 / 申办者:University of Nebraska
药物 / 成分:Vitamin D
登记的停止原因(原文):Study was stopped due to the COVID pandemic
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-01
Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19
编号:NCT04778059登记状态:提前终止企业 / 申办者:US Biotest, Inc.
药物 / 成分:USB002、Placebo
登记的停止原因(原文):Unable to enroll in timely manner due to nature of COVID
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-01
Flunarizine for Treatment Resistant Absence Epilepsy
编号:NCT06153186登记状态:提前终止企业 / 申办者:University of British Columbia
药物 / 成分:Flunarizine Hydrochloride
登记的停止原因(原文):The enrollment wasn't as predicted. We didn't have enough numbers to show statistical significance.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-30
Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer
编号:NCT00540995登记状态:提前终止企业 / 申办者:City of Hope Medical Center
药物 / 成分:busulfan、etoposide、intensity-modulated radiation therapy、allogeneic hematopoietic stem cell transplantation
登记的停止原因(原文):Unable to safely escalate to TMLI doses that were hypothesized to be effective and less toxic than FTBI. Likely due to the giving of Busulfan prior to radiation delivery. Therefore, the study was abandoned and no further patients were accrued.
查看官方原始记录 ↗